Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma

The authors wanted to determine whether adding interferon-alpha (IFN-alpha) to chemotherapy regimens, in either induction or maintenance settings, provides additional survival benefits in follicular non-Hodgkin's lymphoma (NHL). A meta-analysis was performed based on published data from randomi...

Full description

Saved in:
Bibliographic Details
Published inJournal of immunotherapy (1997) Vol. 24; no. 1; p. 58
Main Authors Allen, I E, Ross, S D, Borden, S P, Monroe, M W, Kupelnick, B, Connelly, J E, Ozer, H
Format Journal Article
LanguageEnglish
Published United States 01.01.2001
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The authors wanted to determine whether adding interferon-alpha (IFN-alpha) to chemotherapy regimens, in either induction or maintenance settings, provides additional survival benefits in follicular non-Hodgkin's lymphoma (NHL). A meta-analysis was performed based on published data from randomized controlled clinical trials involving nine separate study populations. Patients receiving IFN-alpha (in either induction or maintenance therapy) had significantly increased 5-year and progression-free survival rates at 3 and 5 years compared with concurrent controls. The advantages of IFN-alpha therapy were most marked in studies using anthracycline-containing induction chemotherapy; in these studies, patients who received IFN-alpha had approximately 20% increased progression-free survival rates compared with controls and a lesser survival advantage. The available literature did not allow a determination of the relative benefit of IFN-alpha in induction or maintenance treatments for NHL or a determination of the optimum duration of IFN-alpha treatment. Although questions remain about its optimal use. IFN-alpha appears to prolong survival time in patients with follicular NHL.
AbstractList The authors wanted to determine whether adding interferon-alpha (IFN-alpha) to chemotherapy regimens, in either induction or maintenance settings, provides additional survival benefits in follicular non-Hodgkin's lymphoma (NHL). A meta-analysis was performed based on published data from randomized controlled clinical trials involving nine separate study populations. Patients receiving IFN-alpha (in either induction or maintenance therapy) had significantly increased 5-year and progression-free survival rates at 3 and 5 years compared with concurrent controls. The advantages of IFN-alpha therapy were most marked in studies using anthracycline-containing induction chemotherapy; in these studies, patients who received IFN-alpha had approximately 20% increased progression-free survival rates compared with controls and a lesser survival advantage. The available literature did not allow a determination of the relative benefit of IFN-alpha in induction or maintenance treatments for NHL or a determination of the optimum duration of IFN-alpha treatment. Although questions remain about its optimal use. IFN-alpha appears to prolong survival time in patients with follicular NHL.
Author Connelly, J E
Ozer, H
Borden, S P
Ross, S D
Allen, I E
Monroe, M W
Kupelnick, B
Author_xml – sequence: 1
  givenname: I E
  surname: Allen
  fullname: Allen, I E
  organization: Babson College, Wellesley, Massachusetts, USA
– sequence: 2
  givenname: S D
  surname: Ross
  fullname: Ross, S D
– sequence: 3
  givenname: S P
  surname: Borden
  fullname: Borden, S P
– sequence: 4
  givenname: M W
  surname: Monroe
  fullname: Monroe, M W
– sequence: 5
  givenname: B
  surname: Kupelnick
  fullname: Kupelnick, B
– sequence: 6
  givenname: J E
  surname: Connelly
  fullname: Connelly, J E
– sequence: 7
  givenname: H
  surname: Ozer
  fullname: Ozer, H
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11211149$$D View this record in MEDLINE/PubMed
BookMark eNo1T8tOwzAQ9KGIPuAXkG-cDF7HjpMjqoAiFXGBc-Uka2Ka2FHsCuXvCSrMHHY0Go121mThg0dCKPA74KW-5zNEpoEJzmEm5-zX0guyAiUkK5XSS7KO8WvO5UKKS7IEEAAgyxU5vmIyzHjTTdFFmgI1MWKcVYsUrXW1qScaLHU-4WhxDJ6ZbmjNbNDBJIc-RfrtUktt6DpXnzoz0vlFtgvN59H520i7qR_a0JsrcmFNF_H6727Ix9Pj-3bH9m_PL9uHPaulLBPTILgSNpeNxkojZpiB1aqEArI8b2wtdVFaXtSVtIUqdGVzlRnV1BUog1KIDbk59w6nqsfmMIyuN-N0-F8tfgAZr1xL
CitedBy_id crossref_primary_10_1016_j_emch_2004_06_001
crossref_primary_10_1080_10428190903254391
crossref_primary_10_1158_1078_0432_154_11_1
crossref_primary_10_1016_S0145_2126_06_80005_6
crossref_primary_10_1053_sonc_2002_33078
crossref_primary_10_1054_ebon_2002_0018
crossref_primary_10_1016_j_blre_2004_09_001
crossref_primary_10_1634_theoncologist_9_4_422
crossref_primary_10_1007_BF02986612
crossref_primary_10_1016_j_critrevonc_2008_01_014
crossref_primary_10_1053_j_seminoncol_2004_02_007
crossref_primary_10_1016_S1155_1984_04_39391_X
crossref_primary_10_1002_14651858_CD004629_pub2
crossref_primary_10_1007_s00277_013_1934_7
crossref_primary_10_1158_2326_6066_CIR_16_0221
crossref_primary_10_1200_JCO_2005_06_146
crossref_primary_10_1080_02841860510029978
crossref_primary_10_3816_CLM_2007_n_034
crossref_primary_10_1002_hon_673
crossref_primary_10_1007_s00277_004_0861_z
crossref_primary_10_1016_S1526_9655_11_70253_6
crossref_primary_10_1016_S0959_8049_02_00087_4
crossref_primary_10_1080_10428190410001723269
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1097/00002371-200101000-00007
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 11211149
Genre Research Support, Non-U.S. Gov't
Meta-Analysis
Journal Article
GroupedDBID ---
.GJ
.Z2
0R~
4Q1
4Q2
4Q3
53G
5VS
8L-
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAQKA
AARTV
AASCR
AAXQO
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABVCZ
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFDTB
AGINI
AHOMT
AHQNM
AHVBC
AIJEX
AINUH
AJIOK
AJNWD
AJNYG
AJZMW
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BOYCO
BQLVK
BS7
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
ERAAH
EX3
F5P
FCALG
FL-
GNXGY
GQDEL
H0~
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
JK8
K8S
KD2
L-C
NPM
N~M
O9-
OAG
OAH
OBS
OCUKA
ODA
OLG
OLW
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XXN
XYM
ZGI
ZXP
ZZMQN
ID FETCH-LOGICAL-c449t-712052f64d7eb7ee3e31f759181366dfc4789f08cb4f8587bf653a5dcb15ae422
ISSN 1524-9557
IngestDate Tue Oct 15 23:22:37 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c449t-712052f64d7eb7ee3e31f759181366dfc4789f08cb4f8587bf653a5dcb15ae422
OpenAccessLink https://doi.org/10.1097/00002371-200101000-00007
PMID 11211149
ParticipantIDs pubmed_primary_11211149
PublicationCentury 2000
PublicationDate 2001-01-01
PublicationDateYYYYMMDD 2001-01-01
PublicationDate_xml – month: 01
  year: 2001
  text: 2001-01-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of immunotherapy (1997)
PublicationTitleAlternate J Immunother
PublicationYear 2001
SSID ssj0026242
Score 1.778875
SecondaryResourceType review_article
Snippet The authors wanted to determine whether adding interferon-alpha (IFN-alpha) to chemotherapy regimens, in either induction or maintenance settings, provides...
SourceID pubmed
SourceType Index Database
StartPage 58
SubjectTerms Aged
Clinical Trials as Topic
Female
Humans
Interferon-alpha - therapeutic use
Lymphoma, Follicular - drug therapy
Male
Middle Aged
Randomized Controlled Trials as Topic
Treatment Outcome
Title Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma
URI https://www.ncbi.nlm.nih.gov/pubmed/11211149
Volume 24
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLU6kBAvE4zvL_kBjYfNKInt2HkEBKqQOk2sk_Y22Y6NENBMbfZQfgc_mOuvJesGAl6iyq7S1vfo5to951yEXlLaaKakIoVtBGxQREGU1C3h8Dg08Hy0PLAJZwf19Jh9POEnk8nPEWvpvNevzY9rdSX_E1UYg7h6lew_RPbipjAAryG-cIUIw_WvYjyzvSIq24pAFanCX7iZqAHrb9bZE2Lp7LJbkKCt3RsMVZO6zXlv7khJXcC7pl37OfTpEqu9b2sIeJfS99Uy9osXmCQZV2AOeE7J-HzB92oJmWgQPXxKrdqPBr7x226ZMuDRIDmDhJOoirNIBLw4nyhH5xMppVaMNDzaUOecG3XTl7AVE2j0cb-S16NfcBHseUTpQQCpJIniY9fcUbjPvod4l969royGqH-e3XDczlNbaEtI3w7kwJ8ApU2819MED970qxI7LBuBXvf1vDFtuuXG5iUUMfM7aDuFDb-JULqLJnaxg27NEr9iB-0eRifz9T6eD8K81T7exYeDx_n6Hvp6CXq473CEHgYg4Aw93Dm8CT0YwBl62EMPD9DDI-i9WuEMvPvo-MP7-bspSX07iGGs6Ykoq4JXrmatsFpY68_ZneANFJO0rltnmJCNK6TRzEkuhXY1p4q3RpdcWVZVD9AN-ED7CGEN5XDRSEoNrLuiVEtDbctVWWupVdM-Rg_jep6eRXOW07zST3478xTdHnD6DN10kA3scygte_0ixPoXplpyQQ
link.rule.ids 780
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Meta-analysis+to+assess+the+efficacy+of+interferon-alpha+in+patients+with+follicular+non-Hodgkin%27s+lymphoma&rft.jtitle=Journal+of+immunotherapy+%281997%29&rft.au=Allen%2C+I+E&rft.au=Ross%2C+S+D&rft.au=Borden%2C+S+P&rft.au=Monroe%2C+M+W&rft.date=2001-01-01&rft.issn=1524-9557&rft.volume=24&rft.issue=1&rft.spage=58&rft_id=info:doi/10.1097%2F00002371-200101000-00007&rft_id=info%3Apmid%2F11211149&rft_id=info%3Apmid%2F11211149&rft.externalDocID=11211149
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1524-9557&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1524-9557&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1524-9557&client=summon